{
  "patient_id": "david_c",
  "extraction_metadata": {
    "extracted_from": [
      "01_Prior_Auth_Request_Form.pdf",
      "02_Laboratory_Results.pdf",
      "03_Colonoscopy_Report.pdf"
    ],
    "extraction_date": "2026-01-25",
    "extraction_method": "clinical_document_extraction"
  },

  "demographics": {
    "first_name": "David",
    "last_name": "Chen",
    "date_of_birth": "1985-08-14",
    "age": 39,
    "gender": "Male",
    "address": {
      "street": "1542 Riverside Drive",
      "city": "Houston",
      "state": "TX",
      "zip": "77002"
    },
    "phone": "713-555-0234",
    "mrn": "DAVID_C",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "insurance": {
    "primary": {
      "payer_name": "Cigna",
      "payer_id": "CIGNA",
      "plan_name": "Cigna HMO-POS",
      "plan_type": "HMO-POS",
      "member_id": "CIG123789456",
      "group_number": "TX-OAP-2024",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  },

  "prescriber": {
    "name": "Dr. Michelle Park",
    "credentials": "MD, FACG",
    "npi": "1654321987",
    "specialty": "Gastroenterology",
    "practice_name": "Houston Gastroenterology Associates",
    "address": {
      "street": "6550 Fannin Street, Suite 1800",
      "city": "Houston",
      "state": "TX",
      "zip": "77030"
    },
    "phone": "713-555-0100",
    "fax": "713-555-0101",
    "tax_id": "XX-XXX1195",
    "dea": "XX9597672",
    "contact": "Clinical Coordinator",
    "contact_email": "pacoordinator@gastrocare.com",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "medication_request": {
    "medication_name": "Infliximab",
    "brand_name": "Inflectra",
    "medication_type": "biosimilar",
    "j_code": "Q5103",
    "dose": "5mg/kg",
    "route": "Intravenous infusion",
    "frequency": {
      "induction": "Weeks 0, 2, 6",
      "maintenance": "Every 8 weeks"
    },
    "duration_requested": "12 months initial authorization",
    "quantity_requested": "4 infusions",
    "site_of_care": "Outpatient infusion center",
    "start_date_requested": "2026-01-01",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "diagnoses": [
    {
      "rank": "primary",
      "icd10_code": "K50.10",
      "description": "Crohn's disease of large intestine without complications",
      "status": "active",
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  ],

  "disease_activity": {
    "assessment_date": "2024-01-10",
    "cdai_score": 228,
    "cdai_interpretation": "Borderline moderate active disease (CDAI 220-450); near the mild-moderate threshold",
    "ses_cd_score": 8,
    "ses_cd_interpretation": "Mild-to-moderate endoscopic activity",
    "disease_severity": "moderate",
    "disease_phenotype": "inflammatory_colonic",
    "disease_location": "Large intestine (transverse and descending colon)",
    "assessment_staleness_note": "Disease activity assessment is over 12 months old — may not reflect current disease status",
    "source_documents": ["01_Prior_Auth_Request_Form.pdf", "03_Colonoscopy_Report.pdf"]
  },

  "clinical_history": {
    "chief_complaint": "Persistent Crohn's disease symptoms despite immunomodulator therapy, requesting biologic escalation",
    "history_of_present_illness": "39-year-old male with Crohn's disease (CDAI 228 as of January 2024, SES-CD 8) who reports inadequate response to conventional therapy. Treatment history: (1) Budesonide 9mg x 13 weeks - partial response, unable to taper; (2) Prednisone 40mg x 24 weeks - steroid-dependent with multiple taper failures; (3) Azathioprine 150mg x 52 weeks (12 months) - inadequate response despite therapeutic 6-TGN levels of 285 pmol. Patient reports 3-4 loose stools daily, mild-to-moderate abdominal discomfort, and intermittent fatigue. No ER visits. No weight loss. No fistulizing or stricturing complications. Last colonoscopy was January 2024 showing mild-to-moderate activity. Current symptoms are manageable but patient desires escalation to biologic therapy for better disease control.",
    "source_document": "01_Prior_Auth_Request_Form.pdf"
  },

  "prior_treatments": [
    {
      "medication_name": "Budesonide",
      "brand_name": "Entocort EC",
      "drug_class": "Corticosteroid (local)",
      "dose": "9mg daily",
      "start_date": "2022-06-15",
      "end_date": "2022-09-15",
      "duration_weeks": 13,
      "outcome": "partial_response",
      "outcome_description": "Partial response to budesonide, but unable to taper without disease flare",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "medication_name": "Prednisone",
      "drug_class": "Corticosteroid (systemic)",
      "dose": "40mg taper",
      "start_date": "2023-01-15",
      "end_date": "2023-06-30",
      "duration_weeks": 24,
      "outcome": "steroid_dependent",
      "outcome_description": "Steroid-dependent disease with multiple taper failures. Disease activity returns upon dose reduction.",
      "adequate_trial": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    },
    {
      "medication_name": "Azathioprine",
      "brand_name": "Imuran",
      "drug_class": "Thiopurine immunomodulator",
      "dose": "150mg (2mg/kg)",
      "start_date": "2023-07-01",
      "end_date": "2024-07-01",
      "duration_weeks": 52,
      "outcome": "inadequate_response",
      "outcome_description": "Inadequate response despite 12 months of optimized therapy with therapeutic 6-TGN levels (285 pmol). Disease activity persisted with CDAI >220 and moderate endoscopic inflammation.",
      "therapeutic_drug_monitoring": {
        "tpmt_genotype": "*1/*1 (Wild type)",
        "6_tgn_level": 285,
        "6_tgn_unit": "pmol/8x10^8 RBC",
        "6_tgn_therapeutic_range": "235-450",
        "6_tgn_interpretation": "Therapeutic - confirms adequate drug exposure",
        "6_mmp_level": 3200,
        "6_mmp_unit": "pmol/8x10^8 RBC",
        "6_mmp_reference": "<5700"
      },
      "adequate_trial": true,
      "acg_guideline_compliant": true,
      "source_document": "01_Prior_Auth_Request_Form.pdf"
    }
  ],

  "laboratory_results": {
    "collection_date": "2024-10-10",
    "accession_number": "26025-141317",
    "ordering_provider": "Dr. Michelle Park",
    "facility": "Clinical Laboratory Services",
    "facility_address": "3500 Gaston Avenue, Dallas, TX 75246",
    "facility_clia": "45D0987654",
    "facility_cap": "7654321-01",
    "report_status": "FINAL",
    "source_document": "02_Laboratory_Results.pdf",

    "panels": {
      "cbc": {
        "panel_name": "Complete Blood Count (CBC)",
        "results": [
          {"test": "WBC", "value": 8.2, "unit": "x10^9/L", "reference_range": "4.5-11.0", "flag": null},
          {"test": "RBC", "value": 4.6, "unit": "x10^12/L", "reference_range": "4.5-5.5", "flag": null},
          {"test": "Hemoglobin", "value": 14.0, "unit": "g/dL", "reference_range": "13.5-17.5", "flag": null},
          {"test": "Hematocrit", "value": 40.1, "unit": "%", "reference_range": "38.8-50", "flag": null},
          {"test": "MCV", "value": 87, "unit": "fL", "reference_range": "80-100", "flag": null},
          {"test": "MCH", "value": 28.7, "unit": "pg", "reference_range": "27-33", "flag": null},
          {"test": "Platelets", "value": 285, "unit": "x10^9/L", "reference_range": "150-400", "flag": null}
        ]
      },
      "cmp": {
        "panel_name": "Comprehensive Metabolic Panel (CMP)",
        "results": [
          {"test": "Sodium", "value": 140, "unit": "mEq/L", "reference_range": "136-145", "flag": null},
          {"test": "Potassium", "value": 4.2, "unit": "mEq/L", "reference_range": "3.5-5.0", "flag": null},
          {"test": "Chloride", "value": 101, "unit": "mEq/L", "reference_range": "98-106", "flag": null},
          {"test": "CO2", "value": 25, "unit": "mEq/L", "reference_range": "23-29", "flag": null},
          {"test": "BUN", "value": 15, "unit": "mg/dL", "reference_range": "7-20", "flag": null},
          {"test": "Creatinine", "value": 1.0, "unit": "mg/dL", "reference_range": "0.7-1.3", "flag": null},
          {"test": "Glucose", "value": 95, "unit": "mg/dL", "reference_range": "70-100", "flag": null},
          {"test": "Calcium", "value": 9.4, "unit": "mg/dL", "reference_range": "8.5-10.5", "flag": null},
          {"test": "Total Protein", "value": 7.0, "unit": "g/dL", "reference_range": "6.0-8.3", "flag": null},
          {"test": "Albumin", "value": 4.0, "unit": "g/dL", "reference_range": "3.5-5.0", "flag": null},
          {"test": "Total Bilirubin", "value": 0.8, "unit": "mg/dL", "reference_range": "0.1-1.2", "flag": null},
          {"test": "Alkaline Phosphatase", "value": 68, "unit": "U/L", "reference_range": "44-147", "flag": null},
          {"test": "AST", "value": 22, "unit": "U/L", "reference_range": "10-40", "flag": null},
          {"test": "ALT", "value": 25, "unit": "U/L", "reference_range": "7-56", "flag": null}
        ]
      },
      "inflammatory_markers": {
        "panel_name": "Inflammatory Markers",
        "results": [
          {"test": "CRP", "value": 8.5, "unit": "mg/L", "reference_range": "0-5", "flag": "H"},
          {"test": "ESR", "value": 16, "unit": "mm/hr", "reference_range": "0-15", "flag": "H"}
        ]
      },
      "gi_markers": {
        "panel_name": "GI-Specific Markers",
        "results": [],
        "note": "Fecal calprotectin was not ordered. This test would provide objective evidence of intestinal inflammation independent of clinical scoring."
      },
      "thiopurine_monitoring": {
        "panel_name": "Thiopurine Monitoring",
        "results": [
          {"test": "TPMT Genotype", "value": "*1/*1", "interpretation": "Wild type - normal metabolism"},
          {"test": "6-TGN", "value": 285, "unit": "pmol/8x10^8 RBC", "reference_range": "235-450 (therapeutic)", "flag": null},
          {"test": "6-MMP", "value": 3200, "unit": "pmol/8x10^8 RBC", "reference_range": "<5700", "flag": null}
        ],
        "interpretation": "Patient has achieved therapeutic 6-TGN levels, confirming adequate azathioprine exposure. Despite therapeutic drug levels, disease remains active, supporting escalation to biologic therapy."
      }
    },

    "interpretation": "Results show mildly elevated CRP (8.5) and borderline ESR (16). No fecal calprotectin obtained — this objective marker of intestinal inflammation would strengthen the clinical picture. CBC and CMP are essentially normal (Hgb 14.0, albumin 4.0). Thiopurine monitoring confirms therapeutic drug levels. Pre-biologic screening complete and cleared. Note: inflammatory markers are only mildly elevated, which may not strongly support the clinical assertion of moderate-to-severe disease activity."
  },

  "procedures": {
    "colonoscopy": {
      "procedure_name": "Colonoscopy with Biopsy",
      "procedure_date": "2024-01-10",
      "procedure_time": "09:30 - 10:15 AM",
      "accession_number": "ENDO260253308",
      "facility": "Houston Gastroenterology Center",
      "facility_address": "3500 Gaston Avenue, Suite 450, Dallas, TX 75246",
      "performed_by": "Dr. Michelle Park, MD, FACG",
      "referring_md": "Dr. Michelle Park",
      "asa_class": "II",
      "indication": "Crohn's disease surveillance and assessment of disease activity on current therapy",
      "staleness_warning": "This colonoscopy was performed over 12 months ago. Payers typically require endoscopic evidence within 6-12 months of PA submission to confirm current disease activity.",
      "sedation": "Moderate sedation (midazolam/fentanyl)",
      "source_document": "03_Colonoscopy_Report.pdf",

      "findings": {
        "terminal_ileum": {
          "description": "Normal appearing mucosa, no ulceration or inflammation",
          "severity": "normal"
        },
        "cecum": {
          "description": "Normal",
          "severity": "normal"
        },
        "ascending_colon": {
          "description": "Mild patchy erythema",
          "severity": "mild"
        },
        "transverse_colon": {
          "description": "Moderate inflammation with scattered aphthous ulcers, edematous mucosa, loss of vascular pattern",
          "severity": "moderate"
        },
        "descending_colon": {
          "description": "Moderate inflammation with linear ulcerations, contact bleeding, skip areas of normal mucosa",
          "severity": "moderate"
        },
        "sigmoid_colon": {
          "description": "Mild patchy erythema",
          "severity": "mild"
        },
        "rectum": {
          "description": "Normal",
          "severity": "normal"
        }
      },

      "endoscopic_score": {
        "score_type": "SES-CD",
        "score_value": 8,
        "interpretation": "mild-to-moderate endoscopic activity"
      },

      "biopsies": [
        {"location": "Transverse colon", "type": "Biopsy", "specimens": 4, "container": "#1"},
        {"location": "Descending colon", "type": "Biopsy", "specimens": 4, "container": "#2"}
      ],

      "pathology": {
        "pathologist": "Dr. Robert Kim, MD",
        "report_date": "2024-01-14",
        "microscopic_findings": "Active chronic colitis with crypt architectural distortion, cryptitis, and focal crypt abscesses. Non-caseating granulomas present.",
        "granulomas_present": true,
        "diagnosis": "Active Crohn's disease, transverse and descending colon"
      },

      "impression": "Mild-to-moderate disease activity in transverse and descending colon. Patient on azathioprine with therapeutic drug levels — consider repeat assessment in 6-12 months to determine if escalation to biologic therapy is warranted."
    }
  },

  "pre_biologic_screening": {
    "status": "COMPLETE",
    "source_document": "02_Laboratory_Results.pdf",
    "clearance_summary": "Pre-biologic screening complete. No contraindication to biologic therapy from infectious disease standpoint. Patient cleared for TNF-alpha inhibitor initiation.",

    "tuberculosis_screening": {
      "status": "COMPLETE",
      "test_performed": "QuantiFERON-TB Gold Plus",
      "result": "Negative",
      "interpretation": "TB screening complete and negative. Patient cleared to initiate TNF inhibitor therapy.",
      "cleared_for_biologic": true
    },

    "hepatitis_b_screening": {
      "status": "COMPLETE",
      "results": [
        {"test": "Hepatitis B Surface Antigen (HBsAg)", "result": "Non-reactive"},
        {"test": "Hepatitis B Core Antibody (anti-HBc)", "result": "Non-reactive"},
        {"test": "Hepatitis B Surface Antibody (anti-HBs)", "result": ">100", "unit": "mIU/mL", "reference": ">10 (immune)"}
      ],
      "interpretation": "Hepatitis B screening complete. Patient is HBV negative with immunity from prior vaccination.",
      "immune_status": "immune_from_vaccination",
      "cleared_for_biologic": true
    },

    "hepatitis_c_screening": {
      "status": "COMPLETE",
      "test_performed": "Hepatitis C Antibody",
      "result": "Non-reactive",
      "cleared_for_biologic": true
    }
  },

  "documentation_gaps": [
    {
      "gap_id": "GAP-001",
      "gap_type": "stale_endoscopic_evidence",
      "description": "Colonoscopy is over 12 months old (performed 2024-01-10). Payers typically require endoscopic evidence within 6-12 months to confirm current disease activity.",
      "required_by_policy": true,
      "impact": "WEAKENS_APPROVAL_LIKELIHOOD",
      "resolution_action": "Obtain updated colonoscopy or sigmoidoscopy with SES-CD scoring to document current endoscopic disease activity",
      "estimated_timeline": "2-4 weeks for scheduling and completion"
    },
    {
      "gap_id": "GAP-002",
      "gap_type": "missing_objective_marker",
      "description": "Fecal calprotectin test not performed. This objective biomarker of intestinal inflammation is increasingly required by payers as objective evidence alongside clinical scoring.",
      "required_by_policy": false,
      "impact": "WEAKENS_APPROVAL_LIKELIHOOD",
      "resolution_action": "Order fecal calprotectin test — elevated result (>250 ug/g) would provide strong objective evidence of active intestinal inflammation independent of clinical scoring",
      "estimated_timeline": "1-2 weeks for results"
    },
    {
      "gap_id": "GAP-003",
      "gap_type": "stale_disease_activity_assessment",
      "description": "CDAI assessment is over 12 months old (last assessed 2024-01-10 at 228). Current disease activity may have changed. A CDAI of 228 is borderline moderate — an updated assessment could either strengthen or weaken the case.",
      "required_by_policy": true,
      "impact": "WEAKENS_APPROVAL_LIKELIHOOD",
      "resolution_action": "Perform updated CDAI assessment at next clinic visit to document current disease activity level",
      "estimated_timeline": "At next scheduled visit"
    },
    {
      "gap_id": "GAP-004",
      "gap_type": "borderline_inflammatory_markers",
      "description": "CRP 8.5 mg/L is only mildly elevated (normal <5). ESR 16 mm/hr is borderline (normal <15). These values do not strongly support moderate-to-severe disease activity. Albumin is normal (4.0).",
      "required_by_policy": false,
      "impact": "WEAKENS_APPROVAL_LIKELIHOOD",
      "resolution_action": "Consider repeating inflammatory markers closer to submission date, or obtain fecal calprotectin as a more specific GI inflammation marker"
    }
  ],

  "pa_criteria_assessment": {
    "diagnosis_confirmed": {
      "met": true,
      "evidence": "ICD-10 K50.10 documented on PA form; colonoscopy confirms active Crohn's disease with non-caseating granulomas in transverse and descending colon",
      "source_documents": ["01_Prior_Auth_Request_Form.pdf", "03_Colonoscopy_Report.pdf"]
    },
    "disease_severity_documented": {
      "met": "partially",
      "evidence": "CDAI 228 (borderline moderate, assessed January 2024 — over 12 months ago), SES-CD 8 (mild-to-moderate, also from January 2024). CRP only mildly elevated at 8.5. No fecal calprotectin obtained. Current disease severity documentation is stale and borderline — may not adequately support moderate-to-severe disease claim.",
      "concerns": [
        "CDAI 228 is just above the 220 threshold for moderate disease",
        "Disease activity assessment is >12 months old",
        "Inflammatory markers (CRP 8.5, ESR 16) are only mildly elevated",
        "No fecal calprotectin to objectively confirm intestinal inflammation",
        "Normal albumin (4.0) does not suggest significant nutritional impact from disease"
      ],
      "source_documents": ["01_Prior_Auth_Request_Form.pdf", "03_Colonoscopy_Report.pdf"]
    },
    "conventional_therapy_failed": {
      "met": true,
      "therapies_tried": [
        {"medication": "Budesonide", "outcome": "partial_response", "duration_adequate": true},
        {"medication": "Prednisone", "outcome": "steroid_dependent", "duration_adequate": true},
        {"medication": "Azathioprine", "outcome": "inadequate_response", "duration_adequate": true, "therapeutic_drug_monitoring": "6-TGN 285 pmol (therapeutic)"}
      ],
      "source_documents": ["01_Prior_Auth_Request_Form.pdf", "02_Laboratory_Results.pdf"]
    },
    "step_therapy_satisfied": {
      "met": true,
      "evidence": "Failed corticosteroids (budesonide 13 weeks, prednisone 24 weeks - steroid-dependent), immunomodulator (azathioprine 52 weeks with therapeutic 6-TGN levels). Meets ACG guideline criteria for biologic escalation.",
      "acg_guideline_compliant": true,
      "source_documents": ["01_Prior_Auth_Request_Form.pdf"]
    },
    "pre_biologic_screening_complete": {
      "met": true,
      "tb_screening": "Negative (QuantiFERON-TB Gold Plus)",
      "hepatitis_b": "Immune from vaccination (HBsAg negative, anti-HBs >100)",
      "hepatitis_c": "Non-reactive",
      "source_documents": ["02_Laboratory_Results.pdf"]
    },
    "fda_approved_indication": {
      "met": true,
      "indication": "Moderate-to-severe Crohn's disease in adults who have had inadequate response to conventional therapy",
      "source_documents": ["01_Prior_Auth_Request_Form.pdf"]
    },
    "therapeutic_drug_monitoring_documented": {
      "met": true,
      "evidence": "6-TGN level 285 pmol/8x10^8 RBC (therapeutic range 235-450) confirms adequate azathioprine exposure. Disease activity persists despite therapeutic levels, objectively supporting need for biologic escalation.",
      "source_documents": ["02_Laboratory_Results.pdf"]
    }
  },

  "overall_pa_readiness": {
    "status": "ADDITIONAL_DOCUMENTATION_RECOMMENDED",
    "blocking_issues": [
      "Colonoscopy is over 12 months old (January 2024) — payers may reject as stale evidence",
      "CDAI 228 is borderline moderate (threshold is 220) — an updated assessment is critical",
      "No fecal calprotectin to objectively confirm active intestinal inflammation",
      "CRP 8.5 and ESR 16 are only mildly elevated — do not strongly support moderate-to-severe claim"
    ],
    "criteria_technically_met": true,
    "approval_risk": "Submitting with current documentation carries significant denial risk due to borderline disease severity markers and stale endoscopic evidence. Cigna reviewers may determine that CDAI 228 with CRP 8.5 does not meet the threshold for moderate-to-severe disease requiring biologic therapy.",
    "recommendation": "Collect additional documentation before submission to significantly strengthen the case: (1) Updated colonoscopy with SES-CD scoring to confirm current endoscopic activity, (2) Fecal calprotectin test to provide objective biomarker evidence, (3) Updated CDAI assessment at next clinic visit. The step therapy documentation is strong (12-month azathioprine trial with TDM), but the current disease activity evidence is the weak link.",
    "strengths": [
      "12-month adequate trial of azathioprine per ACG guidelines",
      "Therapeutic drug monitoring confirms adequate drug exposure (6-TGN 285)",
      "Complete pre-biologic screening with documented results",
      "Pathology-confirmed Crohn's disease with non-caseating granulomas",
      "Clear documentation of steroid dependence"
    ],
    "weaknesses": [
      "Colonoscopy >12 months old — does not reflect current disease status",
      "CDAI 228 is borderline (just 8 points above 220 moderate threshold)",
      "SES-CD 8 indicates mild-to-moderate, not moderate-to-severe endoscopic activity",
      "CRP 8.5 is only mildly elevated — does not strongly indicate active inflammation",
      "ESR 16 is borderline normal",
      "Albumin 4.0 is normal — no nutritional compromise suggesting severe disease",
      "No fecal calprotectin obtained — missing key objective biomarker",
      "No recent ER visits or hospitalizations suggesting clinical urgency"
    ]
  }
}
